Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit

Company Overview - Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to combat multi-drug resistant pathogens in community settings [3] - The company is advancing its first compound, sulopenem, which is a novel penem anti-infective with both oral and IV formulations [3] - Sulopenem has shown potent in vitro activity against a variety of resistant bacteria, including gram-negative, gram-positive, and anaerobic strains [3] Product Development - Iterum has submitted a New Drug Application (NDA) for oral sulopenem aimed at treating uncomplicated urinary tract infections in adult women, which has been accepted for review by the U.S. Food and Drug Administration [3] - The company has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for both oral and IV formulations of sulopenem across seven indications [3] Upcoming Events - Iterum Therapeutics will participate in the 2024 Maxim Healthcare Virtual Summit, with CEO Corey Fishman joining a Fireside Chat on October 16, 2024 [1][2] - The Maxim Healthcare Summit is scheduled to take place from October 15 to 17, 2024, and will be accessible live on MVest [2]